COVID-19 vaccine can be distributed in the U.S. by year-end: Pfizer CEO
By Jahanbee Gupta
Pfizer and BioNTech are planning to produce up to 100 million doses of the vaccine by the end of 2020 and another 1.2 billion doses by the end of 2021.
American pharmaceutical company Pfizer Inc is one of the leading frontrunners in the global COVID-19 vaccine race. The BNT162 mRNA-based vaccine developed by Pfizer along with its German partner BioNTech is expected to be ready by the end of 2020.
Pfizer CEO Albert Bourla said Sunday that they should know if its experimental COVID-19 vaccine works by the end of October. If it receives marketing approval, the vaccine could be distributed in the U.S. by the end of this year, he said. Pfizer and BioNTech are planning to produce up to 100 million doses of the vaccine by the end of 2020 and another 1.2 billion doses by the end of 2021 at sites in Germany and the United States.
In an interview with an American news channel, Bourla said there is a “good chance” they would be able to provide key data from late-stage trials to the Food and Drug Administration (FDA) by the end of October. The company has already manufactured hundreds of thousands of doses so that they can release the vaccine immediately if it gets approval from the regulators.
Pfizer Proposes Expanding Phase 3 Vaccine Trial
On Saturday, Pfizer and BioNTech sought FDA approval to expand their Phase 3 vaccine trials to up to 44,000 participants and include more diverse patient populations. Their initial plan was to include 30,000 participants, which they plan to meet next week, according to a news release. Bourla noted that having a diverse group of volunteers would allow them to collect more data on the safety and efficacy of the vaccine candidate.
Last month, Pfizer and BioNTech shared additional Phase 1 safety and immunogenicity data from their ongoing U.S. study of the vaccine candidate, which has advanced into Phase 2/3 evaluation. The companies have signed an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, subject to clinical success and regulatory approval.